Yoko Akazawa-Ogawa
Overview
Explore the profile of Yoko Akazawa-Ogawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuda T, Akazawa-Ogawa Y, Komaba L, Kiyose N, Miyazaki N, Mizuguchi Y, et al.
Front Immunol
. 2024 Jan;
14:1335462.
PMID: 38292485
Antibody maturation is the central function of the adaptive immune response. This process is driven by the repetitive selection of mutations that increase the affinity toward antigens. We hypothesized that...
2.
Kibria M, Fukutani A, Akazawa-Ogawa Y, Hagihara Y, Kuroda Y
Biomolecules
. 2021 Jun;
11(6).
PMID: 34072518
In this study, we assessed the potential of arginine and lysine solubility-enhancing peptide (SEP) tags to control the solubility of a model protein, anti-EGFR V-7D12, in a thermally denatured state...
3.
Kibria M, Akazawa-Ogawa Y, Hagihara Y, Kuroda Y
Eur J Pharm Biopharm
. 2021 May;
165:13-21.
PMID: 33971271
We previously demonstrated that amorphous aggregates of misfolded V-7D12 antibodies (V-Mis), a potential anti-EGFR drug, can generate a robust serum IgG response. Here we investigate the immunogenic nature, especially the...
4.
Noji M, Samejima T, Yamaguchi K, So M, Yuzu K, Chatani E, et al.
Commun Biol
. 2021 Jan;
4(1):120.
PMID: 33500517
The thermodynamic hypothesis of protein folding, known as the "Anfinsen's dogma" states that the native structure of a protein represents a free energy minimum determined by the amino acid sequence....
5.
Kibria M, Akazawa-Ogawa Y, Rahman N, Hagihara Y, Kuroda Y
Eur J Pharm Biopharm
. 2020 May;
152:164-174.
PMID: 32416134
Amorphous aggregates of therapeutic proteins can provoke an unwanted immune response (anti-drug antibodies; ADAs), but counter-examples have led to some controversy. Amorphous aggregates can possess unique biophysical and biochemical attributes...
6.
Akazawa-Ogawa Y, Komatsu Y, Nakajima Y, Kojima N, Hagihara Y
J Biochem
. 2020 Mar;
168(1):63-72.
PMID: 32154894
Site-specific conjugation of double-stranded DNA using antibodies enables the development of unique applications for antibody-drug conjugates utilizing recent advances in nucleic acid medicines. Here, we describe a novel method to...
7.
Nautiyal K, Kibria M, Akazawa-Ogawa Y, Hagihara Y, Kuroda Y
Biochem Biophys Res Commun
. 2018 Dec;
508(4):1043-1049.
PMID: 30551882
ScFv is emerging as a therapeutic alternative to the full-length monoclonal antibodies due to its small size and low production cost, but its low solubility remains a limiting factor toward...
8.
Noji M, So M, Yamaguchi K, Hojo H, Onda M, Akazawa-Ogawa Y, et al.
Biochemistry
. 2018 Aug;
57(37):5415-5426.
PMID: 30148614
Although ovalbumin (OVA), a main component of hen egg white and a non-inhibitory serpin superfamily protein, has been reported to form fibrillar aggregates, its relationship with amyloid fibrils associated with...
9.
Suzuki T, Mochizuki Y, Kimura S, Akazawa-Ogawa Y, Hagihara Y, Nemoto N
Biochem Biophys Res Commun
. 2018 Aug;
503(3):2054-2060.
PMID: 30119893
Single-domain antibodies (variable domain of the heavy chain of a heavy chain antibody; VHH) are promising reagents for therapeutics and diagnostics because of their stability, cost-effective production and material workability...
10.
Furutani S, Nishio K, Naruishi N, Akazawa-Ogawa Y, Hagihara Y, Yoshida Y, et al.
Anal Sci
. 2018 Mar;
34(3):379-382.
PMID: 29526909
We have developed a compact disc (CD)-shaped microfluidic device for multiple, rapid enzyme-linked immunosorbent assays (ELISA). The device has a versatile design that can be adapted for the detection of...